United States: Federal Circuit Determines Anticipation Of Dependent Claims And Sufficient Evidence Of Commercial Success - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq

07 Sep 2023 0 shares 1 views

United States: Federal Circuit Determines Anticipation Of Dependent Claims And Sufficient Evidence Of Commercial Success - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq

Published 07 Sep 2023

The Court of Appeals for the Federal Circuit (CAFC), on August 16, 2023, affirmed the U.S. Patent and Trademark Office Patent Trial and Appeal Board's (PTAB) decision...

Full Article

United States: The Federal Circuit's First Enablement Decision Since Amgen - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq 26 Sep 2023

Federal Circuit applied Amgen v. Sanofi, 598 U.S. 594 (2013)in deciding that claims 1-4, 19 and 20 of Baxalta's hemophilia patent,..

United States: In Re Cellect – ODP Defense Does Not Impact The Expiration Date Of A Patent With Both PTA And PTE In The Absence Of A Terminal Disclaimer - Oblon, McClelland, Maier & Neustadt, L.L.P
Mondaq 18 Sep 2023
United States: Federal Circuit Reiterates What Constitutes A Motivation To Combine, A Reasonable Expectation Of Success, And Unexpected Results In New Chemical Compounds - Oblon, McClelland, Maier & Neustadt, L.L.P
Mondaq 01 Sep 2023

United States: Federal Circuit Determines Anticipation Of Dependent Claims And Sufficient Evidence Of Commercial Success - Oblon, McClelland, Maier & Neustadt, L.L.P

United States: Federal Circuit Determines Anticipation Of Dependent Claims And Sufficient Evidence Of Commercial Success - Oblon, McClelland, Maier & Neustadt, L.L.P

You might like

Related news coverage

United States: The Federal Circuit's First Enablement Decision Since Amgen - Oblon, McClelland, Maier & Neustadt, L.L.P

Advertisement